Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Iovance Biotherapeutics added another 10% on Friday to reach $14.62, reversing last week's pullback and putting the remaining short base back under severe pressure, with the next earnings print just 26 days away.
The short unwind has continued, but it remains measured. Short interest dropped another 2% on the week to 18.95% of the free float, or roughly 75.2 million shares. That is down from the early September peak near 102 million shares, a reduction of about 26% over the past month. The covering pace has not accelerated into Friday's move. Bears who built positions in August and early September at $6.25 to $8.70 are now sitting on losses of 60% to 130% at current prices. Every day they hold, the cost of that position compounds. Yet capitulation has not arrived. The borrow market explains why there is no mechanical forcing function. Availability has now expanded to 373%, meaning nearly four shares remain available to borrow for every one currently lent out. That is up from 288% a week ago and the loosest reading in the 30-day window. Cost to borrow has dropped to 0.37%, down 42% over the past month and near its lowest level in the history window. The lending market is not squeezing the shorts. They are choosing to hold.
The analyst community is moving faster than the short sellers. Goldman Sachs reinstated coverage with a Buy and a $15 target on September 24, a material signal given that the stock was trading below $10 at the time. Wells Fargo raised its target from $14 to $18 while keeping Overweight, and HC Wainwright lifted to $20. Even the cautious firms are catching up: Baird raised its target to $11 from $6, though it held its Neutral rating. The mean analyst price target sits at $13.30, which is now slightly below the current price at $14.62. The Street's bull case rests on accelerating Amtagvi revenue, with Q2 2026 revenue of $99.3 million up 66% year on year and full-year guidance raised to $410 to $420 million. Bears counter that competitive pressure from CAR-T therapies is real and that the valuation assumes clinical outcomes that remain uncertain. The analyst recommendations rank in the 92nd percentile of all stocks on ORTEX's divergence score, meaning the gap between the most bullish and most bearish views is among the widest in the universe. That spread is itself a signal: this is not a stock where informed opinion has converged.
Options positioning has turned slightly more defensive as the stock recovered. The put/call ratio is 0.53, above its 20-day average of 0.48 and about 1.2 standard deviations elevated. It is not at an extreme: the 52-week high is 0.58 and the low is 0.10, so current readings sit in the cautious-but-not-alarmed range. The ORTEX short score has eased to 61.1 from 66.5 two weeks ago, consistent with the short interest reduction, though a score above 60 still flags a meaningful residual short thesis. Wikipedia attention, which tracks retail engagement, registered a z-score of 3.1 against the prior 90 days as of September 30, reflecting the unusually high retail interest that has accompanied the stock's 68% one-month gain.
On ownership, BlackRock added 5.9 million shares in the quarter to September 30, bringing its stake to 8.2% of shares. State Street added 7.0 million shares to reach 5.4%. Both are passive flows consistent with index weight increases following the stock's rise, but the scale of buying is notable. ORTEX forecasts a 70% probability that IOVA will see a share count increase in the CRSP US Small index at the December 2026 quarterly review, with rank date December 4 and effective date December 23. This is a forecast, not an announcement, but the implied mechanical buying from index trackers is worth carrying into the calculus around year-end flows.
The next earnings print on November 6 is the event that resolves the central disagreement. Short sellers have held at nearly 19% of the float through a 68% one-month rally without breaking. Covering has been steady but not aggressive. Whether that patience survives another strong revenue quarter, or whether Q3 figures disappoint and finally justify the bears' conviction, is what the remainder of October will price in.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
